PubMed Health⌕ Search

PubMed · 15471355

Time resolved solvent rearrangement dynamics.

Abstract

Ultrafast pump-probe studies of I2- recombination in size-selected I2- (CO2)n cluster ions demonstrate long time coherent motions in size-selected clusters and the resulting non-statistical energy flow in the cluster. For I2- photodissociated to produce either I- + I or I- + I*, we identify a solvent-driven energy transfer process without a condensed phase counterpart. The mechanism involved is a Marcus-like solvent-driven curve crossing, with the driving force arising from asymmetric solvation, not just from solvent orientation. By substituting another halogen for one I atom, we "break" the I2- symmetry, and thus obtain direct information on the electron transfer process. New experiments on IBr- (CO2)n photodissociation products confirm the behavior suspected in the I2- studies. Time-resolved experiments on IBr- and theoretical modeling of the dynamics provide quantitative information on the multiple curve crossings encountered in the recombination process. In related investigations, femtosecond negative ion-neutral-positive ion charge reversal apparatus is employed to investigate transient neutral species evolving along a reaction coordinate. We report studies of the rearrangement dynamics of Cu(OH2) produced by photodetachment of the corresponding anion. Following a controlled delay period, a second ultrafast tunable laser pulse initiates resonant multiphoton photoionization of the time-evolving Cu...OH2 complex. The time-resolved Cu+ and Cu+(OH2) signals provide information both on the prompt dissociation of the complex and on energy redistribution between internal rotational and radial modes of the evolving complex. Calculations of the time evolution of the anion geometric configuration on the neutral potential energy surface yield deeper insight into the nature of the rearrangement process and the energy flow within the complex.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Todd Sanford, Django Andrews, Jeff Rathbone, Mark Taylor, Felician Muntean, Matthew Thompson, Anne B McCoy, Robert Parson, W Carl Lineberger. 2004. Time resolved solvent rearrangement dynamics.. https://doi.org/10.1039/b316330j

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗